Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech […]
Read MoreA tragic paradox, Gilead updates, and lots of Pfizer news
Adam Feuerstein/STAT Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, […]
Read MoreASGCT news: Chatter about Vinay Prasad, and newborn screening
NEW ORLEANS — Greetings from the home stretch of American Society of Gene and Cell Therapy conference, where everyone is still talking about Baby KJ and no one wants to […]
Read MoreA dispatch from HIMSS, and bad news for AI research
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and […]
Read MoreVeru, Leqembi, Pfizer, Akero news
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The Trump administration is already making itself felt […]
Read MoreASH 2024: Roundup of news from first day of conference
(This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here.) Greetings from the always-lovely San Diego. […]
Read More